Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stone‐free rate
It is very uncertain whether shock wave lithotripsy changes stone‐free rate compared with dissolution therapy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
1 finding from 1 review
Secondary procedures for residual fragments
It is very uncertain whether shock wave lithotripsy changes secondary procedures for residual fragments compared with dissolution therapy (very low certainty).
1 finding from 1 review
Hospital stay — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with advanced or recurrent endometrial cancer
mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · women with advanced or recurrent endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer
mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).
1 finding from 1 review
Haematological toxicities ‐ Anaemia · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Skin toxicities ‐ Mucositis · women with advanced or recurrent endometrial cancer
mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Respiratory toxicity ‐ Interstitial pneumonitis · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Objective response rate: first‐line trial · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Objective response rate: second/third‐line trials · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in objective response rate: second/third‐line trials compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in wound size · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found